EG 427
Advanced therapies specifically targeting neural circuits starting with neuro-urology
EG 427 has developed a platform technology to create targeted gene therapies tailored to specific neuronal populations implicated in major pathologies. The first indication is in neurogenic detrusor overactivity (NDO), a form of spastic bladder common in SCI and neurodegenerative conditions such as multiple sclerosis and Parkinson's with significant impact on a person's quality of life and high risk of secondary complications.
Technology
How they’re delivering breakthroughs
- EG 427's targeted gene therapies allow to target specific neuronal populations with high precision
- The genetic vectors have a low immunogenic profile, increasing safety and allowing for repeat-usage of the therapeutic
- The therapeutics are delivered at extremely low volumes, in a highly localized manner, increasing safety
Impact
How they’re making a difference
- Bladder dysfunction, and in particular neurogenic detrusor overactivity is a major pain point for people living with SCI and neurodegenerative conditions
- The current standard of care has significant safety and quality of life drawbacks in addition to an eventual development of immunity to key alternative approaches such as repeated botox injections into the bladder.
Learn more about EG 427
Portfolio
